美国医疗保险类风湿关节炎患者生物制剂超敏反应风险比较
该研究基于美国Medicare数据,纳入80,587例类风湿关节炎生物制剂新使用者,比较不同生物制剂超敏反应风险。结果显示6个月累积发生率均低于1%,但利妥昔单抗和英夫利西单抗与超敏反应风险关联最强,绝对发生率较低。
要点
- 利妥昔单抗和英夫利西单抗与超敏反应风险关联最强。
- 所有生物制剂6个月超敏反应累积发生率均低于1%。
- 调整后静脉利妥昔单抗、英夫利西单抗、阿巴西普和托珠单抗超敏反应风险显著高于注射抗TNF抑制剂。
核心结论
- 在类风湿关节炎生物制剂使用者中,利妥昔单抗和英夫利西单抗与超敏反应风险关联最强。
- 所有生物制剂暴露的超敏反应绝对发生率均较低。
研究设计与样本
- 基于美国Medicare数据,识别英夫利西单抗、阿巴西普、利妥昔单抗、托珠单抗、戈利木单抗及注射生物制剂的新使用者。
- 使用验证算法识别超敏反应,计算6个月累积发生率和给药后0-1、2-14、15-30天的发生率。
- 采用调整稳健Poisson回归比较不同生物制剂间超敏反应风险,并进行巢式病例交叉设计敏感性分析。
主要发现
- 共识别725,591次生物制剂给药和248例超敏反应,涉及80,587例新使用者。
- 超敏反应中26.9%发生于静脉阿巴西普使用者,4.6%发生于利妥昔单抗,5.8%发生于静脉托珠单抗,22.9%发生于英夫利西单抗,39.7%发生于注射抗TNF抑制剂。
- 所有生物制剂6个月超敏反应累积发生率均低于1%。
- 超敏反应发生率范围为2.4(阿巴西普)至239.5(利妥昔单抗)每10^6人日。
- 以注射抗TNF抑制剂0-30天为参照,调整后利妥昔单抗、英夫利西单抗、阿巴西普和托珠单抗静脉给药与超敏反应风险显著升高相关。
关键数值与推荐
- 6个月累积发生率:所有生物制剂均<1%。
- 发生率范围:2.4(阿巴西普)至239.5(利妥昔单抗)每10^6人日。
临床怎么用
- 临床使用利妥昔单抗和英夫利西单抗时应关注超敏反应风险。
- 尽管相对风险存在差异,所有生物制剂的超敏反应绝对发生率较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypersensitivity reactions (HSRs) can occur with any of the available biologic agents used to treat rheumatoid arthritis (RA). We compared drug-specific risks for HSRs among RA patients enrolled in the US Medicare program. METHODS: Using Medicare data, we identified new users of infused infliximab, abatacept, rituximab, tocilizumab, golimumab, and injected biologic agents. After identifying HSRs using validated algorithms, for each biologic agent, we calculated the cumulative incidence over 6 months and the incidence rates (IRs) in 0-1, 2-14, and 15-30 days of administration. For each biologic agent administration, followup started on the infusion/injection date and ended at HSR, subsequent biologic agent administration, death, coverage loss, 30-day followup, or December 31, 2013, whichever occurred first. Adjusted robust Poisson regression was used to compare the HSR risks across biologic agents. A sensitivity analysis was conducted using a nested case-crossover design. RESULTS: We identified 725,591 biologic agent administrations and 248 HSRs among 80,587 new users of biologic agents. Of these, 26.9% occurred in users of intravenous abatacept, 4.6% in rituximab, 5.8% in intravenous tocilizumab, 22.9% in infliximab, and 39.7% in injectable anti-tumor necrosis factor inhibitors (anti-TNFi). The cumulative incidence of HSRs over 6 months for all biologic agents was low (<1%).The IRs for HSRs ranged from 2.4 (abatacept) to 239.5 (rituximab) per 106 person-days. After adjustment, and using injectable anti-TNFi over 0-30 days as the referent, rituximab, infliximab, abatacept, and tocilizumab infusions were associated with a statistically significant higher risk of HSR. The sensitivity analysis yielded similar results. CONCLUSION: Among RA patients taking biologic agents, rituximab and infliximab were most strongly associated with HSRs. The absolute IRs of HSR events for all biologic agent exposures were low.
引用
- Yun H, Xie F, Beyl RN, et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017. PMID: 27813327. doi:10.1002/acr.23141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。